dipyridamole has been researched along with Alloxan Diabetes in 19 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole prevented the progression of DN by elevating endogenous levels of protecting adenosine, leading to reduction in inflammation and intrinsic apoptosis." | 7.81 | Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis. ( Abd El Galil, KH; Al-Gayyar, MM; Elsherbiny, NM, 2015) |
| "Dipyridamole anti-platelet therapy has previously been suggested to ameliorate chronic tissue ischemia in healthy animals." | 7.77 | Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress. ( Bir, SC; Branch, BG; Greber, E; Kevil, CG; Pardue, S; Patel, RP; Pattillo, CB; Shen, X, 2011) |
| "Dipyridamole prevented the progression of DN by elevating endogenous levels of protecting adenosine, leading to reduction in inflammation and intrinsic apoptosis." | 3.81 | Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis. ( Abd El Galil, KH; Al-Gayyar, MM; Elsherbiny, NM, 2015) |
| "Dipyridamole anti-platelet therapy has previously been suggested to ameliorate chronic tissue ischemia in healthy animals." | 3.77 | Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress. ( Bir, SC; Branch, BG; Greber, E; Kevil, CG; Pardue, S; Patel, RP; Pattillo, CB; Shen, X, 2011) |
| "We assessed the effect of dipyridamole, RA-642 and mopidamol, on lenticular opacities in a model of experimental diabetic cataracts in rats." | 3.69 | The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats. ( de la Cruz, JP; García-Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F, 1994) |
| "Adenosine was administered once at the time of islet transplantation." | 1.35 | Prevention of early loss of transplanted islets in the liver of mice by adenosine. ( Itoh, T; Kojima, D; Matsuoka, N; Mera, T; Nakano, M; Nitta, T; Yamashita, Y; Yasunami, Y, 2009) |
| "Treatment with aspirin plus dipyridamole caused an inhibition of the platelet production of thromboxane B2 and a decrease in the vascular synthesis of prostacyclin." | 1.30 | Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. ( De la Cruz, JP; García Campos, JM; Moreno, A; Muñoz, M; Sánchez de la Cuesta, F, 1997) |
| "Treatment with dipyridamole, mopidamol, and RA-642 caused 2." | 1.29 | The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus. ( De La Cruz, JP; García Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 8 (42.11) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balakumar, P | 2 |
| Varatharajan, R | 1 |
| Nyo, YH | 1 |
| Renushia, R | 1 |
| Raaginey, D | 1 |
| Oh, AN | 1 |
| Akhtar, SS | 1 |
| Rupeshkumar, M | 1 |
| Sundram, K | 1 |
| Dhanaraj, SA | 1 |
| Elsherbiny, NM | 1 |
| Al-Gayyar, MM | 1 |
| Abd El Galil, KH | 1 |
| Cosyns, B | 1 |
| Droogmans, S | 1 |
| Hernot, S | 1 |
| Degaillier, C | 1 |
| Garbar, C | 1 |
| Weytjens, C | 1 |
| Roosens, B | 1 |
| Schoors, D | 1 |
| Lahoutte, T | 1 |
| Franken, PR | 1 |
| Van Camp, G | 1 |
| Nitta, T | 1 |
| Itoh, T | 1 |
| Matsuoka, N | 1 |
| Mera, T | 1 |
| Kojima, D | 1 |
| Nakano, M | 1 |
| Yamashita, Y | 1 |
| Yasunami, Y | 1 |
| Pattillo, CB | 1 |
| Bir, SC | 1 |
| Branch, BG | 1 |
| Greber, E | 1 |
| Shen, X | 1 |
| Pardue, S | 1 |
| Patel, RP | 1 |
| Kevil, CG | 1 |
| Sharma, NK | 1 |
| Mahadevan, N | 1 |
| Onozato, ML | 1 |
| Tojo, A | 1 |
| Goto, A | 1 |
| Fujita, T | 1 |
| Karpen, CW | 1 |
| Pritchard, KA | 1 |
| Merola, AJ | 1 |
| Panganamala, RV | 1 |
| de la Cruz, JP | 4 |
| Moreno, A | 4 |
| Mérida, F | 2 |
| García-Campos, J | 1 |
| Sánchez de la Cuesta, F | 4 |
| Vallon, V | 1 |
| Osswald, H | 1 |
| García Campos, J | 2 |
| Muñoz, M | 1 |
| García Campos, JM | 1 |
| Abdel-aleem, S | 1 |
| El-Guindy, N | 1 |
| Sallam, TI | 1 |
| Hughes, GC | 1 |
| Lowe, JE | 1 |
| Peredo, HA | 1 |
| Filinger, EJ | 1 |
| Cheng, JT | 1 |
| Chi, TC | 1 |
| Liu, IM | 1 |
| Usta, CK | 1 |
| Adan, G | 1 |
| Ozdem, SS | 1 |
| Honour, AJ | 1 |
| Hockaday, TD | 1 |
| Mann, JI | 1 |
| Okada, N | 1 |
| Aizawa, T | 1 |
| Yokokawa, N | 1 |
| Kobayashi, M | 1 |
| Moriya, T | 1 |
| Shigematsu, S | 1 |
| Shirota, T | 1 |
| Komatsu, M | 1 |
| Shinoda, T | 1 |
| Yamada, T | 1 |
19 other studies available for dipyridamole and Alloxan Diabetes
| Article | Year |
|---|---|
Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats.
Topics: Animals; Blood Glucose; Cholesterol; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropat | 2014 |
Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis.
Topics: Adenosine; Animals; Apoptosis; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2015 |
Effect of streptozotocin-induced diabetes on myocardial blood flow reserve assessed by myocardial contrast echocardiography in rats.
Topics: Animals; Capillaries; Cardiomyopathies; Contrast Media; Coronary Circulation; Diabetes Mellitus, Exp | 2008 |
Prevention of early loss of transplanted islets in the liver of mice by adenosine.
Topics: Adenosine; Animals; Antibodies; Blood Glucose; CD11b Antigen; CD4 Antigens; Diabetes Mellitus, Exper | 2009 |
Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress.
Topics: Animals; Diabetes Mellitus, Experimental; Dipyridamole; Disease Models, Animal; Hindlimb; Hyperchole | 2011 |
Adenosine transport blockade restores attenuated cardioprotective effects of adenosine preconditioning in the isolated diabetic rat heart: potential crosstalk with opioid receptors.
Topics: Adenosine; Animals; Cardiotonic Agents; Diabetes Mellitus, Experimental; Dipyridamole; Female; Heart | 2013 |
Effect of combination therapy with dipyridamole and quinapril in diabetic nephropathy.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blotting, Western; Cr | 2003 |
Alterations of the prostacyclin-thromboxane ratio in streptozotocin induced diabetic rats.
Topics: Animals; Aorta, Thoracic; Arachidonic Acid; Arachidonic Acids; Blood Platelets; Diabetes Mellitus, E | 1982 |
The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats.
Topics: Animals; Blood Glucose; Cardiotonic Agents; Cataract; Diabetes Mellitus, Experimental; Dipyridamole; | 1994 |
Dipyridamole prevents diabetes-induced alterations of kidney function in rats.
Topics: Adenosine; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipyridamole; Glomerular Filtrat | 1994 |
The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dipyridamole; Epopros | 1996 |
Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Diabetes Mellitus, Experimental; Dipyridamole; Epopr | 1997 |
Stimulation of long-chain fatty acid uptake by dipyridamole in isolated myocytes.
Topics: Animals; Diabetes Mellitus, Experimental; Dipyridamole; Fatty Acids; Fatty Acids, Nonesterified; Hea | 1999 |
Effect of dipyridamole on prostanoid production in rat isolated atria.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Diabetes Mellitus, Experimental; Dinoprostone; Dipyridamole; | 1999 |
Activation of adenosine A1 receptors by drugs to lower plasma glucose in streptozotocin-induced diabetic rats.
Topics: Adenosine; Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Dipyridamole; Disea | 2000 |
The effects of adenosine on isolated right atrial preparations from streptozotocin-diabetic rats.
Topics: Adenosine; Animals; Atrial Function, Right; Blood Glucose; Diabetes Mellitus, Experimental; Dipyrida | 2001 |
The reversibility by dipyridamole of the increased sensitivity of in vivo platelet aggregation in rabbits after alloxan.
Topics: Adenosine Diphosphate; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipyridamole; Male; | 1976 |
Abnormal molecular weight profile of urinary protein in rats with streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipyridamole; Electrophoresis, | 1992 |
Effect of antiplatelet drug therapy on the retinal vascular pattern in experimental diabetes mellitus.
Topics: Animals; Aspirin; Collagen; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dipyridamole; Dr | 1990 |